Nordic Nanovector
ISIN: NO0010597883 | Ticker: NANOV | LEI: 5967007LIEEXZXG6DK30
Country: Norway
Nordic Nanovector is a leader in the development of CD37-targeted radionuclide therapies for haematological cancers.
Nordic Nanovector’s pipeline includes:
- Betalutin®, clinically safe and effective CD37-targeting radioimmunotherapy incorporating the beta emitter lutetium-177 and the murine antibody lilotomab for treatment of non-Hodgkin's lymphoma (NHL)
- Humalutin®, IND ready CD37-targeting radioimmunotherapy incorporating the beta emitter lutetium-177 and the chimeric antibody NNV003 for treatment of non-Hodgkin's lymphoma (NHL)
- 89Zr-NNV003, CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors
- Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-particle generating radionuclide lead-212,
- Multiple fully humanized anti-CD37 antibodies with different effector mechanisms for treatment of haematological cancers and autoimmune diseases
- Undisclosed discovery projects in solid tumor indications
2009
Served areaWorldwide
HeadquartersKjelsåsveien 168B, 0884 Oslo – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 314,610,000.00 | 296,672,000.00 | 109,645,000.00 |
| Noncurrent Assets | N/A | 5,684,000.00 | 5,943,000.00 | 537,000.00 |
| Property Plant And Equipment | N/A | 1,394,000.00 | 766,000.00 | 379,000.00 |
| Investments In Subsidiaries | N/A | N/A | 0.00 | 0.00 |
| Current Assets | N/A | 308,926,000.00 | 290,729,000.00 | 109,108,000.00 |
| Trade And Other Current Receivables | N/A | 14,951,000.00 | 13,023,000.00 | 10,392,000.00 |
| Other Current Receivables | N/A | 14,951,000.00 | 13,023,000.00 | N/A |
| Cash and cash equivalents | 470,824,000.00 | 293,975,000.00 | 277,706,000.00 | 98,716,000.00 |
| Current Prepayments And Other Current Assets | N/A | N/A | 13,023,000.00 | 10,392,000.00 |
| Equity And Liabilities | N/A | 314,610,000.00 | 296,672,000.00 | 109,645,000.00 |
| Equity | 388,008,000.00 | 178,668,000.00 | 140,516,000.00 | 63,842,000.00 |
| Issued Capital | N/A | 15,878,000.00 | 19,616,000.00 | 23,207,000.00 |
| Share Premium | N/A | 118,371,000.00 | 110,573,000.00 | 695,000.00 |
| Additional Paidin Capital | N/A | 61,565,000.00 | 69,157,000.00 | 65,855,000.00 |
| Liabilities | N/A | 135,942,000.00 | 156,156,000.00 | 45,803,000.00 |
| Noncurrent Liabilities | N/A | 7,381,000.00 | 4,461,000.00 | 1,520,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 5,025,000.00 | 4,461,000.00 | N/A |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | N/A | 4,461,000.00 | 1,520,000.00 |
| Current Liabilities | N/A | 128,561,000.00 | 151,695,000.00 | 44,283,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 65,862,000.00 | 65,960,000.00 | 9,093,000.00 |
| Trade And Other Current Payables To Related Parties | N/A | N/A | 0.00 | 0.00 |
| Current Tax Liabilities Current | N/A | 803,000.00 | 1,068,000.00 | 759,000.00 |
| Other Current Liabilities | N/A | 59,685,000.00 | 79,159,000.00 | 34,272,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Revenue From Sale Of Goods | 0.00 | 0.00 | 0.00 |
| Employee Benefits Expense | 78,301,000.00 | 91,638,000.00 | 78,527,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | 11,371,000.00 | 11,202,000.00 |
| Depreciation Expense | 14,895,000.00 | 11,371,000.00 | N/A |
| Profit Loss From Operating Activities | -434,161,000.00 | -442,434,000.00 | -317,361,000.00 |
| Finance Income | 1,610,000.00 | 1,219,000.00 | 3,289,000.00 |
| Finance Costs | 860,000.00 | 636,000.00 | 259,000.00 |
| Profit Loss Before Tax | -416,161,000.00 | -440,138,000.00 | -310,372,000.00 |
| Income Tax Expense Continuing Operations | 914,000.00 | 1,165,000.00 | 869,000.00 |
| Profit (loss) | -417,075,000.00 | -441,303,000.00 | -311,241,000.00 |
| Profit Loss Attributable To Owners Of Parent | -417,075,000.00 | -441,303,000.00 | -311,241,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -417,075,000.00 | -441,303,000.00 | -311,241,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -18,490,000.00 | -1,229,000.00 | -4,428,000.00 |
| Dividends Paid Classified As Operating Activities | N/A | N/A | 0.00 | 0.00 |
| Dividends Received Classified As Operating Activities | N/A | N/A | 0.00 | 0.00 |
| Interest Paid Classified As Operating Activities | N/A | -471,000.00 | -414,000.00 | N/A |
| Interest Received Classified As Operating Activities | N/A | -1,590,000.00 | -1,122,000.00 | -3,164,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -398,206,000.00 | -403,458,000.00 | -409,079,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 185,000.00 | 259,000.00 | 5,628,000.00 |
| Interest Received Classified As Investing Activities | N/A | 1,590,000.00 | 1,122,000.00 | 3,164,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 1,405,000.00 | 863,000.00 | -2,464,000.00 |
| Proceeds From Issuing Shares | N/A | 231,505,000.00 | 423,568,000.00 | 250,808,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 13,751,000.00 | 10,429,000.00 | 5,522,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 471,000.00 | -414,000.00 | -66,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 201,462,000.00 | 385,096,000.00 | 228,125,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 18,490,000.00 | 1,229,000.00 | 4,428,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -176,894,000.00 | -16,269,000.00 | -178,990,000.00 |
| Cash and cash equivalents | 470,824,000.00 | 293,975,000.00 | 277,706,000.00 | 98,716,000.00 |
Please note that some sums might not add up.
NO0010597883
LEI5967007LIEEXZXG6DK30
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.